AI in Preemptive Medicine and Population Health

By Sumona Bose

February 22, 2024

Introduction

One emerging field that holds promise for the future is preemptive medicine. This novel concept aims to delay or prevent the onset of chronic diseases through the use of Artificial Intelligence (AI) techniques, genomic analysis, and environmental interaction data. In this article, we will explore the role of AI in preemptive medicine and its impact on population health and health economics.

Advancements in Preemptive Medicine

Preemptive medicine combines AI technology with genomic analysis and environmental data to identify individuals at risk of developing chronic diseases. By analysing vast amounts of data, AI algorithms can detect patterns and predict disease progression with high accuracy. AI can analyse genetic markers to identify individuals with a higher likelihood of developing conditions. These can be diabetes, hypertension, cancer, or dementia.

AI and machine learning (ML) technologies have been effectively applied in parsing vast amounts of data produced by genomic technologies. Deep-coverage whole-genome sequencing of 8,392 individuals from European and African backgrounds helped pinpoint single-nucleotide variants and copy-number variations in Lipoprotein (a). This study discovered that certain LPA risk genotypes pose a higher relative risk for developing cardiovascular diseases compared to the direct measurement of Lipoprotein (a) levels.

These advancements in preemptive medicine can inform healthcare by shifting the focus from reactive treatment to proactive prevention. By identifying at-risk individuals early on, healthcare providers can intervene with targeted interventions and lifestyle modifications. This improves patient outcomes and reduces the burden on healthcare systems by minimising resource use and allocation.

www.frontiersin.org
Figure 1: A simplified schematic representation of one of the several machine learning (ML) technologies that can be utilised for diagnosis and management of endocrine disorders.

Challenges to Put into Practice

AI holds great promise in preemptive medicine, there is a need to address several challenges and ethical considerations. The longitudinal nature of variations in human disease, heterogeneity of healthcare data, and personal data confidentiality pose challenges for AI techniques. The need for informed consent from patients, supportive policies, efficient business models, and unpredictable reimbursement further complicate the integration of AI in healthcare.

Furthermore, interpreting “digital biomarkers” obtained through AI analysis is not always straightforward. Certain AI algorithms may outperform older techniques in specific population cohorts. Their implementation across diverse populations may not necessarily result in better diagnoses or outcomes. There is a risk of over-diagnosis and over-treatment in certain patient cohorts. This highlights the importance of careful interpretation and clinical judgment.

Conclusion

AI can elevate preemptive medicine and improve population health outcomes. By leveraging AI techniques, genomic analysis, and environmental data, healthcare providers can identify individuals at risk of developing chronic diseases. This will aid in improving health outcomes by designing interventions.

Reference url

Recent Posts

U.S. withdraws from WHO
     

U.S. Withdraws from WHO: Impact on Global Health Security and Relations

🚨 *What does the U.S. withdrawing from the WHO mean for global health?*
President Trump’s executive order to begin the withdrawal process raises serious concerns about the future of global health security. From financial disparities to a shift in international partnerships, the implications could reshape our collective ability to combat pandemics and health crises.

Dive into our article to understand the potential impacts on health outcomes and the quest for new alliances.

#SyenzaNews #globalhealth #healthcarepolicy

semaglutide NAION risk
    

Semaglutide NAION Risk: EMA Review Initiated Amid Conflicting Evidence

🔍 Is semaglutide linked to vision loss?

The European Medicines Agency’s PRAC is currently reviewing the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing medicines, including popular treatments like Ozempic and Wegovy. With recent studies yielding conflicting evidence, this review is crucial for patient safety and the future of these therapies.

Read the full article to understand the implications and what this could mean for healthcare providers and patients alike!

#SyenzaNews #Pharmaceuticals #HealthcarePolicy

cervical cancer screening
        

Cost-Effective Cervical Cancer Screening Strategies for Women with HIV in KwaZulu-Natal

💡 *Are single-visit cervical cancer screenings the key to better health outcomes in high HIV prevalence areas?*
A recent study from KwaZulu-Natal, South Africa reveals that repeat single-visit cervical cancer screening using HPV DNA testing is not only the most effective but also the most cost-effective approach for women living with HIV. This aligns with WHO recommendations for comprehensive cervical cancer elimination strategies.

Explore the insights and implications of this vital research that could transform cervical cancer prevention in resource-limited settings.

#SyenzaNews #HealthEconomics #oncology #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.